Skip to main content

Court Victory for Pfizer

A judge denies a bid by Novo Nordisk to halt sales of the inhaled insulin Exubera.

Pfizer

(PFE)

said a federal judge has denied a bid by Denmark's

Novo Nordisk

(NVO)

to halt sales of the inhaled insulin Exubera.

Novo Nordisk, which is working on its own inhaled insulin,

sued Pfizer in August for patent infringement. On Thursday, a judge in New York rejected Novo Nordisk's request for a preliminary injunction until the patent suit is resolved. A Pfizer spokesman said a trial date hasn't been set.

Pfizer developed Exubera with

Scroll to Continue

TheStreet Recommends

Nektar Therapeutics

(NKTR)

.

Approved by the FDA in January, Exubera, a dry powder form of insulin, has been

reaching markets slowly since July.

Pfizer says a full-scale launch of the drug to primary care physicians will begin in January.

Novo Nordisk is working on AERx, an inhaled form of liquid insulin, using technology developed by

Aradigm

undefined

. Analysts say it will still take about four years for this product to be available.